omadacycline
(2)
Paratek Pharmaceuticals
Paratek Pharmaceuticals is a Boston-based commercial-stage biopharmaceutical company built on tetracycline chemistry to fight drug-resistant bacterial infections. Its flagship antibiotic NUZYRA (omadacycline) is a once-daily oral and IV broad-spectrum drug approved by the FDA in 2018 for community-acquired bacterial pneumonia and acute skin infections, and it is also being developed under a major BARDA contract as a national-stockpile countermeasure against pulmonary anthrax. Paratek also originated SEYSARA (sarecycline) for acne. Now privately held by Gurnet Point Capital and Novo Holdings after a 2023 acquisition, the company positions itself as a defender of public health against the slow-moving pandemic of antimicrobial resistance.
Michael Bigham
Michael F. Bigham is a veteran biopharmaceutical executive and investor who spent nearly a decade as Chairman and CEO of Paratek Pharmaceuticals, guiding the company through the FDA approval and commercial launch of NUZYRA (omadacycline) - a novel tetracycline-class antibiotic tackling drug-resistant bacterial infections. A Stanford MBA and CPA with roots in Gilead Sciences' early days, he has built, funded, and led companies across the full arc of drug development. He now operates as founder and managing director of Firebrand River Capital.